FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3110839340> ?p ?o ?g. }

• W3110839340 endingPage "583.e4" @default.
• W3110839340 startingPage "576" @default.
• W3110839340 abstract "BackgroundAtopic dermatitis (AD) is associated with a substantial burden on quality of life (QoL).ObjectiveTo evaluate the effects of tralokinumab on health-related QoL in patients with moderate-to-severe AD using patient-reported outcomes.MethodsThis was a phase 2b, randomized, double-blind, placebo-controlled, dose-ranging study in adults with moderate-to-severe AD. The patients received subcutaneous tralokinumab or placebo (1:1:1:1) every 2 weeks for 12 weeks and class 3 topical corticosteroid cream or ointment at least once daily from the run-in to end of follow-up. Patient-reported outcome end points were change from baseline to week 12 in the Dermatology Life Quality Index (dermatology life quality index (DLQI); prespecified secondary objective), the Short Form 36 Health Survey (SF-36) version 2, and sleep interference numeric rating scale score (prespecified exploratory objectives).ResultsA total of 204 patients were randomized to placebo (n = 51) or tralokinumab (45 mg, n = 50; 150 mg, n = 51; 300 mg, n = 52). Tralokinumab 300 mg every 2 weeks improved total Dermatology Life Quality Index vs placebo at week 12 (placebo-adjusted mean change, −3.51 [95% confidence interval, −6.00 to −1.02]). At week 12, both the mental component summary (4.23 [0.98-7.47]) and the physical component summary (4.26 [1.83-6.69]) and all 8 domains of the Short Form 36 Health Survey were improved in patients treated with tralokinumab 300 mg vs placebo. Sleep interference was improved at week 12 with all tralokinumab doses vs placebo.ConclusionTralokinumab improved health-related QoL in patients with moderate-to-severe atopic dermatitis, providing further evidence of the value of targeting interleukin-13 in such patients.Trial RegistrationClinicalTrials.gov identifier: NCT02347176; https://clinicaltrials.gov/ct2/show/NCT02347176." @default.
• W3110839340 created "2020-12-21" @default.
• W3110839340 creator A5006526834 @default.
• W3110839340 creator A5011739266 @default.
• W3110839340 creator A5017462779 @default.
• W3110839340 creator A5024365532 @default.
• W3110839340 creator A5038514239 @default.
• W3110839340 creator A5044664487 @default.
• W3110839340 creator A5048797041 @default.
• W3110839340 creator A5049151102 @default.
• W3110839340 creator A5073722593 @default.
• W3110839340 creator A5083749846 @default.
• W3110839340 date "2021-05-01" @default.
• W3110839340 modified "2023-10-17" @default.
• W3110839340 title "Health-related quality of life with tralokinumab in moderate-to-severe atopic dermatitis" @default.
• W3110839340 cites W1527957830 @default.
• W3110839340 cites W1612101546 @default.
• W3110839340 cites W2012962257 @default.
• W3110839340 cites W2028924443 @default.
• W3110839340 cites W2030298480 @default.
• W3110839340 cites W2058535990 @default.
• W3110839340 cites W2058562555 @default.
• W3110839340 cites W2089467255 @default.
• W3110839340 cites W2096991001 @default.
• W3110839340 cites W2118862186 @default.
• W3110839340 cites W2143138262 @default.
• W3110839340 cites W2300630231 @default.
• W3110839340 cites W2496806206 @default.
• W3110839340 cites W2520198258 @default.
• W3110839340 cites W2606310824 @default.
• W3110839340 cites W2623278488 @default.
• W3110839340 cites W2772411615 @default.
• W3110839340 cites W2783829013 @default.
• W3110839340 cites W2807789068 @default.
• W3110839340 cites W2883568898 @default.
• W3110839340 cites W2888917798 @default.
• W3110839340 cites W2889552403 @default.
• W3110839340 cites W2897204831 @default.
• W3110839340 cites W2904694536 @default.
• W3110839340 cites W2921312740 @default.
• W3110839340 cites W2939040277 @default.
• W3110839340 cites W2949491609 @default.
• W3110839340 cites W2951700339 @default.
• W3110839340 cites W2954612861 @default.
• W3110839340 doi "https://doi.org/10.1016/j.anai.2020.12.004" @default.
• W3110839340 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33333295" @default.
• W3110839340 hasPublicationYear "2021" @default.
• W3110839340 type Work @default.
• W3110839340 sameAs 3110839340 @default.
• W3110839340 citedByCount "12" @default.
• W3110839340 countsByYear W31108393402021 @default.
• W3110839340 countsByYear W31108393402022 @default.
• W3110839340 countsByYear W31108393402023 @default.
• W3110839340 crossrefType "journal-article" @default.
• W3110839340 hasAuthorship W3110839340A5006526834 @default.
• W3110839340 hasAuthorship W3110839340A5011739266 @default.
• W3110839340 hasAuthorship W3110839340A5017462779 @default.
• W3110839340 hasAuthorship W3110839340A5024365532 @default.
• W3110839340 hasAuthorship W3110839340A5038514239 @default.
• W3110839340 hasAuthorship W3110839340A5044664487 @default.
• W3110839340 hasAuthorship W3110839340A5048797041 @default.
• W3110839340 hasAuthorship W3110839340A5049151102 @default.
• W3110839340 hasAuthorship W3110839340A5073722593 @default.
• W3110839340 hasAuthorship W3110839340A5083749846 @default.
• W3110839340 hasBestOaLocation W31108393401 @default.
• W3110839340 hasConcept C118552586 @default.
• W3110839340 hasConcept C126322002 @default.
• W3110839340 hasConcept C142724271 @default.
• W3110839340 hasConcept C159110408 @default.
• W3110839340 hasConcept C16005928 @default.
• W3110839340 hasConcept C168563851 @default.
• W3110839340 hasConcept C169900460 @default.
• W3110839340 hasConcept C1862650 @default.
• W3110839340 hasConcept C202061045 @default.
• W3110839340 hasConcept C204787440 @default.
• W3110839340 hasConcept C27081682 @default.
• W3110839340 hasConcept C2776173921 @default.
• W3110839340 hasConcept C2776245837 @default.
• W3110839340 hasConcept C2778329239 @default.
• W3110839340 hasConcept C2779134260 @default.
• W3110839340 hasConcept C2779951463 @default.
• W3110839340 hasConcept C2780699399 @default.
• W3110839340 hasConcept C2983189541 @default.
• W3110839340 hasConcept C2991744798 @default.
• W3110839340 hasConcept C44249647 @default.
• W3110839340 hasConcept C71924100 @default.
• W3110839340 hasConceptScore W3110839340C118552586 @default.
• W3110839340 hasConceptScore W3110839340C126322002 @default.
• W3110839340 hasConceptScore W3110839340C142724271 @default.
• W3110839340 hasConceptScore W3110839340C159110408 @default.
• W3110839340 hasConceptScore W3110839340C16005928 @default.
• W3110839340 hasConceptScore W3110839340C168563851 @default.
• W3110839340 hasConceptScore W3110839340C169900460 @default.
• W3110839340 hasConceptScore W3110839340C1862650 @default.
• W3110839340 hasConceptScore W3110839340C202061045 @default.
• W3110839340 hasConceptScore W3110839340C204787440 @default.
• W3110839340 hasConceptScore W3110839340C27081682 @default.
• W3110839340 hasConceptScore W3110839340C2776173921 @default.

• next